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Associations Elementary!
He et al., page 667
Determining how variants exert effects that can be de-
tected by genome-wide association studies (GWASs),
and specifically how some of these variants might alter
gene expression, in humans has largely been limited to
looking at nearby, cis-acting SNP-gene interactions. Typi-
cally, expression of genes within a certain distance to a
variant is examined. However, to look for trans-acting
effects, one might need to look much farther away. In
this study, He et al. devise a genome-wide approach
that circumvents these limitations by using a method
named Sherlock. Much as a detective compares finger-
prints at a crime scene to a fingerprint database, Sherlock
matches eQTL disease signatures to significant GWAS
variants in disease cohorts and identifies those variants
that contribute to altered gene expression at the
genome-wide level. Conveniently, the data sets can
come from different individuals, meaning that existing
data could be analyzed with Sherlock. He et al. identify
both cis- and trans-acting variants, including SNPs that
alter expression of UBE2L3, EFS, and LYNX1 in Crohn
disease and SNPs that alter expression of TSPAN8,
PURB, GNB5, and JAZF1 in a type 2 diabetes cohort.
Clever detectives might uncover the functional effects
of many more GWAS variants through the use of
Sherlock.FOXP2 Targets Are Targets of Positive Selection
Ayub et al., page 696
Genes that allow us to use and develop language skills
are incredibly important, and unsurprisingly, some
show signals of positive selection. One such gene,
FOXP2, which encodes a transcription factor that acts
on many downstream genes, has received a substantial
amount of attention because of its association with
speech and language disorders in humans and its asso-
ciation with vocalization in other animals. Ayub and
colleagues wondered whether, like FOXP2, these down-
stream targets would also show signals of positive
selection. They identified putative FOXP2 targets from1Scientific Editor, AJHG; 2Deputy Editor, AJHG
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identified control genes by using a matching algorithm
based on gene length, GC content, average recombina-
tion rate, and distance from the target. With the target
and control genes identified, they searched for evidence
of positive selection in 1000 Genomes populations,
including Europeans, Chinese, Japanese, and Yoruba. A
strong signal of selection could be detected in 139 genes
in Europeans, but the signal failed to reach genome-
wide significance in other populations. Many of these
signals were localized to FOXP2-binding sites in genes,
such as CNTNAP2 and RBFOX1, that might be involved
in nervous-system development. Additionally, Europeans
had an enrichment of variation in these binding sites,
which might explain why positive selection could be
detected in this population. Not only does this work
tell us more about the FOXP2 network, but the algo-
rithm used to identify matching genes could also be
used in a variety of studies where comparable control
genes are required.GWAS for All (Phenotypes)
Schifano et al., page 744
GWASs can provide insight into the genetic architecture
of a variety of human traits and diseases. In the
frequently used case-control study design, SNPs associ-
ated with a particular phenotype are identified in the
comparison of affected versus unaffected (often disease-
free) individuals. Although the experiments are far from
simple, the approach is relatively straightforward. More
challenging, however, is deciding how to employ the
GWAS approach to identify SNPs that are associated
with the additional phenotypes that are measured in
the clinical work-up. Indeed, the number of so-called sec-
ondary phenotypes assessed is often quite large, and to
ignore this information seems imprudent. The devil,
however, is in the details: no consensus has been reached
regarding how to control for confounding factors such
as ascertainment bias. In this issue, Schifano et al. pre-
sent the scaled multiple-phenotype association test
(SMAT), a scaled marginal model that can test the effect
of a given SNP on secondary continuous phenotypes
in case-control studies. When applied to a lung-cancery of Human Genetics. All rights reserved.
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case-control study, SMAT identified several interesting
SNPs linked to smoking behavior; future work, however,
will need to evaluate exactly how these variants could
influence smoking behavior. Many groups have rich
phenotypic information at their fingertips, and SMAT
might provide just the tool with which they can analyze
their data.XPF: A Hub for DNA Repair
Kashiyama et al., page 807; Bogliolo et al, page 800
DNA repair is essential for all living things: in humans, the
havoc wreaked by missteps in this process is evident in
numerous inherited disorders, as well as in somatic muta-
tions seen in various cancers. Although much progress
has been made in understanding the biochemical nature
of the different repair pathways, any hope for targeted
treatment options requires the careful characterization of
just which mutations cause which phenotypes. In this
issue, Kashiyama et al. and Bogliolo et al. identify muta-
tions in ERCC1 and ERCC4 in individuals with Cockayne
syndrome and Fanconi Anemia. Together, ERCC1 and
ERCC4 (also known as XPF) form a heterodimeric endonu-
clease (ERCC1-XPF) that is required for the repair of spe-
cific types of DNA lesions. Notably, mutations in ERCC4
have been linked to xeroderma pigmentosum and a form
of progeria. These new findings show that depending on
the nature of the mutation, variants in ERCC4 can cause
one of several disorders. This disease-causing capacity is
most likely related to the ability of XPF to function in three
critical DNA repair pathways: TCR, NER, and FA crosslink
repair. The authors’ work suggests explanations for this
separation of function, and further characterization of
known mutations, coupled with the discovery of addi-
tional mutant alleles, will no doubt enhance our under-
standing of this specificity.640 The American Journal of Human Genetics 92, 639–640, May 2, 2A SNP Implicated in Weight Loss after Gastric
Bypass
Hatoum et al., page 827
The reasons that some people lose substantially more
weight after gastric bypass than others are not entirely clear.
Related individuals, even in different living environments,
have similar weight-loss outcomes—in contrast to unre-
lated individuals living together, who do not have corre-
lated weight loss. This, and other data, suggests that there
is a genetic component to weight loss after gastric bypass,
but this component has not been fully elucidated. To iden-
tify the underlying genetic factors that might contribute to
thesedivergent responses,Hatoumet al. performedaGWAS
in a group of individuals who have undergone gastric
bypass surgery. One SNP, rs17702901, located near ST8SIA2
and SLCO3A, reached genome-wide significance. Interest-
ingly, none of the previously identified variants associated
with increased BMI or type 2 diabetes showed a significant
associationwithweight loss, suggesting adifferent underly-
ing mechanism for weight loss after surgery and weight
gain. To determine the possible influence of rs17702901
on the two nearby genes, the authors measured expression
levels. They found that increased ST8SIA2 expression in
certain tissues was associated with increased weight loss.
SNPs in ST8SIA2 have been associated with autism, bipolar
disorder, and schizophrenia in humans, and mutations
in the mouse ortholog cause obesity. ST8SIA2 encodes
a sialytransferase, but it is unclear how this protein might
alter the metabolic processes that are affected by gastric-
bypass surgery. Although the rs17702901 genotype cannot
independently predict weight-loss outcome, perhaps this
information could be integrated into current standards
to determine preoperatively whether individuals would
benefit from surgery. Alternatively, knowledge gained
from follow-up studies could lead to the development of
an alternative weight-loss therapy.013
